Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Becoming amazing at Systems administration: Individual and Expert Tips- Old photos misrepresented as aftermath of political party supporters' brawl in Bangladesh
- Vacation destinations in America
- Pick Your Favored kind of soup
- Creative Style: 10 Architects Reclassifying the Business
- The Most Encouraging New companies to Look Out For
- I tried a macho, creatine-loaded cereal “for men.” Did I mention I'm a woman?
- Step by step instructions to Pick an Incineration Urn: Variables to Consider
- Arctic sea ice hits lowest winter level as heat records are shattered worldwide
